Alcohol withdrawal: Difference between revisions

From IDWiki
(added phenobarbital info and rearranged sections)
m (Text replacement - "Clinical Presentation" to "Clinical Manifestations")
Line 11: Line 11:
*Drinking all day long
*Drinking all day long


==Clinical Presentation==
==Clinical Manifestations==


*6 to 12 hours after last drink: shaking, headache, sweating, anxiety, nausea, or vomiting
*6 to 12 hours after last drink: shaking, headache, sweating, anxiety, nausea, or vomiting

Revision as of 01:52, 21 July 2020

Background

Risk factors for severe withdrawal

  • Severity predicted by PAWSS scale: if score ≤3 can manage as outpatient
  • History of alcohol withdrawal, especially if previously severe (e.g. delirium tremens)
  • Age
  • Alcohol tolerance
  • Concurrent sedative medications
  • Major medical comorbidities
  • Drinking all day long

Clinical Manifestations

  • 6 to 12 hours after last drink: shaking, headache, sweating, anxiety, nausea, or vomiting
  • 12 to 24 hours after last drink: confusion, hallucinosis (with awareness of reality), tremor, or agitation
  • 24 to 48 hours after last drink: seizures
  • 48 hours after last drink: delirium tremens, high blood pressure, and fever
    • Can persist anywhere from 4 to 12 days

Investigations

  • Monitor electrolytes and extended electrolytes for refeeding syndrome

Management

  • Give the balance of risks (minimal) and benefits (potentially large), almost all patients treated for alcohol withdrawal should receive supplemental Thiamine
    • Standard: 250 mg IM/IV q24h x3d
    • High-dose: 500 mg IV q8h x3

Benzodiazepine protocols

  • If history of seizures: diazepam 20mg q1h x3 doses before starting CIWA
  • Can use diazepam, lorazepam (if liver disease), or Chlordiazepoxide
  • Start CIWA-Ar (Clinical Institute Withdrawal Assessment - Alcohol revised) q1h
    • CIWA-Ar 10-20
      • First-line: diazepam 10mg PO/IV q1h
      • Liver dysfunction: lorazepam 2mg PO/IV/IM q1h
      • Liver failure, age >60, chronic opioid use, acute respiratory illness: lorazepam 1mg PO/IV/IM q1h
    • CIWA-Ar >20
      • 1L NS bolus over 30 minutes followed by 200mL/h
      • First-line: diazepam 20mg PO/IV q1h
      • Liver dysfunction: lorazepam 4mg PO/IV/IM q1h
      • Liver failure, age >60, chronic opioid use, acute respiratory illness: lorazepam 2mg PO/IV/IM q1h
    • Discontinue CIWA-Ar protocol after two consecutive scores <10

Phenobarbital protocols

General protocol

  • Load 10 mg/kg IV up front over 30min (if has not received significant benzodiazepines)
  • Then give 130-260 mg IV prn for mild to severe withdrawal symptoms
  • Titrate to effect; there is no maximum dose
  • Maintenance with 100-200 mg PO/IM q1h prn

CAMH protocol

  • Loading: phenobarbital 120 mg po q1h until phenobarbital loading effect score is 3 to 4, then stop loading
  • Maintenance: phenobarbital 60 mg po qid
  • Taper:
    • Decrease by 30 mg each day from a starting dose of phenobarbital 60 mg po qid
    • 60/60/60/60, 60/30/60/60, 60/30/30/60, 60/30/30/30, 30/30/30/30, 30/–/30/30, 30/–/–/30, 30/–/–/–, stop
    • Takes 8 days
  • Phenobarbital loading effect scale
    • Nystagmus: absent (0); present on extension of lateral gaze (1); easily elicited and sustained (2); coarse, sustained nystagmus (3)
    • Dysarthria: absent (0); minor slurring of some words (1); moderate slurring frequently (2); severe slurring, unintelligible (3)
    • Ataxia: absent (0); mildly unsteady on tandem gait (1); moderately unsteady on regular gait (2); needs support on regular gait (3)
    • Emotional lability: normal, as before loading (0); some mood change (1); obvious mood change, inappropriate (2); uninhibited, mood swings (3)

Seizures